Pin1 Inhibitors Demonstrate Novel Antiviral Mechanism Against HSV-1 by Trapping Virus in Cell Nucleus
Key Insights
Pin1 inhibitors (search), including H-77 (search) and four newly developed compounds, successfully stopped HSV-1 (search) replication at concentrations as low as 1 μM in laboratory tests.
The inhibitors work through a unique mechanism by stabilizing nuclear membrane structure, physically trapping viral particles within the cell nucleus and preventing their escape.
Researchers aim to develop Pin1 inhibitors (search) as host-directed therapeutics that could be less prone to drug resistance compared to traditional antivirals.
A novel class of antiviral compounds has shown promising results against herpes simplex virus 1 (search) (HSV-1 (search)) through an unprecedented mechanism that physically traps the virus within infected cells, according to research published in Antiviral Research on July 25.
The study, led by researchers at Hiroshima University, demonstrates that Pin1 inhibitors (search) can effectively suppress HSV-1 (search) replication by targeting a host enzyme rather than the virus directly. HSV-1, which causes oral herpes (search) and affects between 50% and 90% of people worldwide, remains dormant in the body after initial infection and can reactivate throughout a person's life, causing cold sores or fever blisters.
Targeting Host Factor Pin1
The research focused on peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (search) (Pin1 (search)), an enzyme that regulates protein stability, function, and cellular structure. HSV-infected cells over-express Pin1, making it an attractive therapeutic target.
"This study revealed that the host factor Pin1 (search) is a crucial therapeutic target for the proliferation of HSV-1 (search). Pin1 inhibitors (search) potently suppress HSV-1 replication at low concentrations," said Takemasa Sakaguchi, a professor at the Graduate School of Biomedical and Health Sciences at Hiroshima University.
Laboratory Results Show Complete Viral Suppression
In laboratory tests using VeroE6 cells infected with HSV-1 (search), researchers evaluated the Pin1 (search) inhibitor H-77 (search) alongside four newly developed Pin1 inhibitors (search). The compounds demonstrated dose-dependent antiviral activity, with viral effects on cells becoming less pronounced as inhibitor concentrations increased and completely disappearing at 1 μM.
Importantly, any viral particles released from treated cells were rendered non-infectious, suggesting the inhibitors not only reduce viral replication but also compromise the viability of progeny viruses.
Novel Mechanism Creates "Impregnable Defensive Wall"
The most significant finding reveals how Pin1 inhibitors (search) prevent viral escape through structural modifications to the nuclear membrane. The inhibitors work by stabilizing the nuclear lamina, creating a physical barrier that traps viral particles within the cell nucleus.
"The nuclear lamina initially functions as a 'barrier' when nucleocapsids of progeny viruses, that replicate within the nucleus, bud from the nuclear membrane. Pin1 (search) overexpressed by the virus removes this barrier," Sakaguchi explained. "However, through the action of the Pin1 inhibitor H-77 (search), this barrier is rather reinforced, forming a thick and robust lamina layer. This demonstrates that H-77 transforms the nuclear lamina into an 'impregnable defensive wall,' physically blocking the escape of viruses from the nucleus of the cell."
Clinical Implications and Future Development
The findings are particularly significant for immunocompromised patients, for whom HSV-1 (search) infections can be serious and potentially fatal. Current antiviral treatments face challenges with drug resistance, making the development of alternative therapeutic approaches crucial.
Pin1 inhibitors (search) represent a host-directed therapeutic approach that may be less susceptible to resistance development since they target host cellular machinery rather than viral components directly. This mechanism has already shown promise against other viruses, including cytomegalovirus and SARS-CoV-2.
Research Trajectory
The research team plans to expand their investigations to evaluate Pin1 inhibitors (search) against diverse viruses to determine the full therapeutic range of these compounds. Simultaneously, they will focus on optimizing compound structures to develop more potent and selective drugs.
"The ultimate goal for the future is to aim for the clinical application of Pin1 inhibitors (search) as 'host-directed therapeutics,' which are less likely to cause drug resistance," Sakaguchi noted. "To achieve this, we will first evaluate their efficacy against diverse viruses to clarify the treatable range. Simultaneously, research to optimize the compound structure is essential for creating more potent and selective drugs."